GeoVax Labs, Inc. will present clinical progress for its CM04S1 COVID-19 vaccine candidate at the Emerging Growth Conference on September 25, 2025. The presentation will highlight interim results demonstrating the vaccine's effectiveness in immunocompromised patient populations where current vaccines have shown limitations.
Recent data presented at the International Workshop on Chronic Lymphocytic Leukemia showed that CM04S1 achieved the study's immune response primary endpoint in CLL patients, while the comparator mRNA vaccine did not. Based on the Data Safety Monitoring Board recommendation, further enrollment is proceeding exclusively in the CM04S1 arm. Additional results from the European Society of Clinical Microbiology and Infectious Disease meeting demonstrated robust, durable T-cell and cross-variant antibody responses in immunocompromised blood cancer and post-transplant patients, with no serious adverse events reported.
David Dodd, Chairman and CEO of GeoVax, stated that these results underscore the promise of CM04S1 as a multi-antigen solution for patients left behind by first-generation COVID-19 vaccines. The company's MVA platform is demonstrating potential to deliver broad, durable immune protection where it is needed most. Register here to attend the conference: https://goto.webcasts.com/starthere.jsp?ei=1717091&tp_key=c78a55764a&sti=govx.
The clinical significance of these findings lies in addressing a critical public health gap. Immunocompromised individuals, including cancer patients and transplant recipients, have remained vulnerable to COVID-19 despite vaccination efforts with existing vaccines. CM04S1's demonstrated ability to elicit immune responses in these populations represents a potential breakthrough in protecting those most at risk. A replay will be made available following the event on www.EmergingGrowth.com and the Emerging Growth YouTube channel.
This development matters because it addresses the ongoing need for effective COVID-19 protection in vulnerable populations who cannot adequately respond to current vaccines. The implications extend beyond immediate patient care to broader public health strategies, potentially reducing hospitalizations and severe outcomes in high-risk groups. The vaccine's multi-antigen approach and demonstrated safety profile suggest it could become an important tool in managing COVID-19 among immunocompromised individuals worldwide.
